Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
|Articles|November 9, 2011
Depression scales links
Advertisement
Interactive, mobile-ready
Includes:
Patient Health Questionnaires
7-item General Anxiety Disorder Assessment
Major Depression Inventory
Hamilton Anxiety Scale
Geriatric Depression Assessment
Advertisement
Related to this article
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Pharmacologic Approaches to Reducing Suicide Risk
2
Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia
3
Fewer Than 1 in 5 Young Patients With First-Episode Psychosis Adhere to Antipsychotics
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5